The FDA has approved the first generic version of Mylan’s EpiPEN and EpiPen Jr (epinephrine) auto injector used to treat emergency allergic reactions, such as the life-threatening anaphylaxis. The generic epinephrine auto-injector has been green flagged to market in 0.3 mg and 0.15 mg strengths for adults and pediatric patients weighing more than 33 pounds. FDA Commissioner Scott Gottlieb, M.D. states “Today’s approval of the first generic version of the most-widely prescribed epinephrine auto-injector in the U.S. is part of our longstanding commitment to advance access to lower cost, safe and effective generic alternatives once patents and other exclusivities no longer prevent approval.” Read the full FDA news release here.
- Keep Your Genes On: How to Set Patients’ Expectations of PGx Testing
- FDA Approves a New Version of OTC Inhaler Primatene Mist
- New Physical Activity Guidelines for Americans: “Move more, and sit less”
- FDA Announces an Emergency Use Authorization for “Fingerstick” Ebola Test that Uses a Portable Battery Reader
- French Study finds Association with Organic Food Consumption and Reduced Risk of Cancer